Literature DB >> 23123720

[Platinum agent-induced nephrotoxicity via organic cation transport system].

Atsushi Yonezawa1.   

Abstract

Platinum agents are widely used in cancer chemotherapy. Cisplatin, carboplatin, oxaliplatin and nedaplatin have a common chemical structure consisting of platinum, carrier groups and leaving groups, and undergo the similar mechanism of cytotoxicity. Only cisplatin induces nephrotoxicity, although the molecular mechanism involved is unclear. Organic cation transporter (OCT)/SLC22A, and multidrug and toxin extrusion (MATE)/SLC47A play a role in renal handling of cationic drug in the kidney. We focused on a role of transporters in nephrotoxicity of platinum agents. OCT2 mediates the transport of cisplatin and is the determinant of cisplatin-induced nephrotoxicity. In addition, MATE1 protects cisplatin-induced nephrotoxicity. Oxaliplatin, which was a superior substrate of the luminal efflux transporter, MATE2-K as well as OCT2, did not show nephrotoxicity. Moreover, carboplatin and nedaplatin were not transported by these transporters. Substrate specificity could regulate the features of platinum agents. Recent findings indicate that organic cation transporters are key to the nephrotoxicity of platinum agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123720     DOI: 10.1248/yakushi.12-00211

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  9 in total

1.  Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).

Authors:  Qing Li; Dong Guo; Zhongqi Dong; Wei Zhang; Lei Zhang; Shiew-Mei Huang; James E Polli; Yan Shu
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-31       Impact factor: 4.219

2.  Short-term control of diet affects cisplatin-induced acute kidney injury through modulation of mitochondrial dynamics and mitochondrial GSH.

Authors:  Ji Su Kim; Yong Kwon Han; Min Jung Kong; Kwon Moo Park
Journal:  Physiol Rep       Date:  2022-06

3.  Glioblastoma development in mouse brain: general reduction of OCTs and mislocalization of OCT3 transporter and subsequent uptake of ASP+ substrate to the nuclei.

Authors:  Lilia Y Kucheryavykh; Kimberleve Rolón-Reyes; Yuriy V Kucheryavykh; Serguei Skatchkov; Misty J Eaton; Priscila Sanabria; William D Wessinger; Mikhail Inyushin
Journal:  J Neurosci Neuroeng       Date:  2014-02

4.  Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.

Authors:  Qing Li; Hong Yang; Dong Guo; Taolan Zhang; James E Polli; Honghao Zhou; Yan Shu
Journal:  Drug Metab Dispos       Date:  2016-01-29       Impact factor: 3.922

Review 5.  Role of solute carriers in response to anticancer drugs.

Authors:  Qing Li; Yan Shu
Journal:  Mol Cell Ther       Date:  2014-05-27

6.  Electron microscopy in rat brain slices reveals rapid accumulation of Cisplatin on ribosomes and other cellular components only in glia.

Authors:  Lidia Zueva; Yomarie Rivera; Lilia Kucheryavykh; Serguei N Skatchkov; Misty J Eaton; Priscila Sanabria; Mikhail Inyushin
Journal:  Chemother Res Pract       Date:  2014-12-28

7.  Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.

Authors:  Zulfan Zazuli; Susanne Vijverberg; Elise Slob; Geoffrey Liu; Bruce Carleton; Joris Veltman; Paul Baas; Rosalinde Masereeuw; Anke-Hilse Maitland-van der Zee
Journal:  Front Pharmacol       Date:  2018-09-27       Impact factor: 5.810

8.  Mitochondrial NADP+-dependent isocitrate dehydrogenase deficiency increases cisplatin-induced oxidative damage in the kidney tubule cells.

Authors:  Min Jung Kong; Sang Jun Han; Jee In Kim; Jeen-Woo Park; Kwon Moo Park
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

9.  Fragmentation of kidney epithelial cell primary cilia occurs by cisplatin and these cilia fragments are excreted into the urine.

Authors:  Min Jung Kong; Sang Hong Bak; Ki-Hwan Han; Jee In Kim; Jeen-Woo Park; Kwon Moo Park
Journal:  Redox Biol       Date:  2018-09-25       Impact factor: 11.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.